Arca
Skip to content
Tools
Tools

Acute ischemic stroke

Drug research and approvals for acute ischemic stroke: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 339 studies of acute ischemic stroke are recruiting on ClinicalTrials.gov, Health Canada has authorized 12 drug trials for it since 2013, and FDA has 0 approved and 4 open orphan designations naming it.

  • Recruiting worldwide: 339
  • Trials authorized in Canada: 12
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 339 recruiting on ClinicalTrials.gov ↗

How its trials ended

2,189 ClinicalTrials.gov studies of ischemic stroke in general, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 388 whose ending is known, 37% met their primary endpoint, 12% missed it and 51% stopped early.

  • Ongoing72733%
  • Completed, result not reported67831%
  • Status unknown39618%
  • Met its primary endpoint1426%
  • Stopped: other or unclear1095%
  • Missed its primary endpoint472%
  • Stopped: enrollment or feasibility432%
  • Stopped: lack of efficacy191%
  • Stopped: sponsor or business decision141%
  • Stopped: funding9<1%
  • Stopped: safety5<1%

Trials authorized in Canada

The 10 newest of 12; search them all in Canada trials
Sep 25, 2026A phase 2a multicenter, randomized, double-blind, placebo-controlled, parallel-arm domain within the act-global trial platform, to evaluate the dose-response,…NTS-521Neurotrauma Sciences, LLCOngoing
Jul 10, 2026Safety and efficacy of intravenous thrombolysis in patients with ischemic stroke on treatment with direct oral anticoagulants: do-it – the doac intravenous…Tnkase / ActivaseInsel Gruppe AG, Inselspital (University Hospital) BernPending
Jan 24, 2025Optimizing reperfusion to improve outcomes and neurologic function (ORION): a multicenter, double-blind, placebo controlled, randomized, parallel-group, phase…JX10Corxel Pharmaceuticals, Co, LtdOngoing
Nov 1, 2024Phase 2/3 adaptive design, randomized double-blind placebo-controlled study to evaluate the safety and efficacy of DM199 for the treatment of acute ischemic…DM199 (rinvecalinase alfa)DiaMedica TherapeuticsOngoing
Oct 1, 2024A multicenter, double-blinded, placebo-controlled, single ascending dose, twopart, randomized, phase 2 clinical trial to assess safety, tolerability,…BB-031Basking BiosciencesOngoing
Aug 15, 2024An investigator-initiated phase 3 multicentre open-label blinded-endpoint randomized controlled trial to evaluate the efficacy and safety of very low-dose…EdoxabanSunnybrook Research InstitutePending
Dec 5, 2023A phase I, open-label, multicenter, pharmacokinetic, pharmacodynamic, and safety study of tenecteplase in adult patients with acute ischemic strokeTnkaseRochePending
Dec 10, 2021A phase II, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of balovaptan in patients with acute ischemic…Balovaptan (RO5285119)RocheClosed
Sep 18, 2020A multicenter, randomized, double-blinded, placebo-controlled, parallel group, single-dose design to determine the efficacy and safety of nerinetide in…Nerinetide (NA-1)Nono IncClosed
Dec 18, 2019A randomized, double-blind, placebo-controlled proof-of-concept study to assess the safety and efficacy of elezanumab in acute ischemic strokeElezanumab (ABT-555)AbbVieClosed

FDA orphan designations

Approved first, then open designations, newest first
Oct 14, 2024GlyburideTreatment of large territory acute ischemic strokeRemedy Pharmaceuticals, Inc.Designated
Jan 12, 2017GlyburideTreatment of severe cerebral edema in patients with acute ischemic strokeRemedy Pharmaceuticals, Inc.Designated
Apr 11, 2014H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Se…Treatment of acute ischemic stroke patients presenting within 3 hours of symptom onsetNoNO, Inc.Designated
Apr 18, 2011Tissue Plasminogen activatorTreatment of acute ischemic stroke (AIS) in children age 16 years and younger.Catherine Amlie-Lefond, MDDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.